Goldman Sachs Commences Coverage for Mineralys with Buy Rating
Tuesday, 2 April 2024, 18:37
Goldman Sachs Initiates Coverage of Mineralys
Goldman Sachs has recently introduced a buy rating for Mineralys Therapeutics (MLYS) based on the positive prospects of its hypertension drug candidate, lorundrostat.
Key Points:
- Buy Rating: Goldman Sachs commences coverage of Mineralys with a buy rating.
- Drug Data: Cites upcoming data release on lorundrostat, Mineralys' hypertension drug candidate.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.